Galindo et al. similarly demonstrate in a prospective clinical trial with 257 donors that donor and recipient outcomes are comparable for both hCG and GnRH triggers, and the risk of OHSS for donors is considerably reduced using a GnRH antagonist protocol with GnRH agonist triggering [24]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.